Illumina reported $1.08 billion in Q3 revenues—roughly flat year‑over‑year—and beat adjusted EPS expectations with $1.34, citing strength in clinical sequencing outside China. The company raised its full‑year 2025 revenue and EPS guidance modestly while forecasting a small overall revenue decline versus last year on a constant‑currency basis. Illumina repurchased $120 million of stock during the quarter and ended with about $1.05 billion in cash. Management emphasized execution in clinical markets and a return to growth outside China as drivers for the updated outlook.